BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
See today's BioWorld Asia
Home
» OctoPlus Shares Surge After Dr. Reddy's $36M Buyout Bid
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
OctoPlus Shares Surge After Dr. Reddy's $36M Buyout Bid
Oct. 24, 2012
By
Cormac Sheridan
No Comments
The management of Dutch drug delivery specialist OctoPlus NV agreed to a €27.4 million (US$35.8 million) cash offer from Indian generics firm Dr. Reddy's Laboratories Ltd.
BioWorld Asia